Drugs / Rituximab and Hyaluronidase Human
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04759586 Background | Oct 2021 → Dec 2026 expected | primary mediastinal large B-cell lymphoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rituximab and Hyaluronidase Human | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04759586 ↗ |
| Route | Subcutaneous | “Given SC” NCT04759586 ↗ |